ClinicalTrials.gg

Program

AMG 691

A development code.

Its studies are mostly in Respiratory Tract Diseases · Asthma, led by Amgen.

Furthest: phase 1, since Oct 9, 20242 company-led studies, 2 open or runningNext primary completion: Mar 17, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen22 open or runningphase 1since Oct 9, 2024Oct 9, 2024Mar 17, 2027phase 1 · NCT07745907

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2024First study: phase 1 study in AsthmaFirst studyNCT06637371 · 21 enrolled · United States, Australia, Belgium and more
  2. Jul 30, 2026Phase 1 study in Respiratory Tract DiseasesNCT07745907 · 28 enrolled · United States

Ahead

  1. Mar 17, 2027Primary completion: phase 1 study in Respiratory Tract DiseasesNCT07745907
  2. Apr 10, 2027Primary completion: phase 1 study in AsthmaNCT06637371

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07745907Respiratory Tract Diseases · United States1Active, not recruitingMar 17, 202728
NCT06637371Asthma · United States, Australia, Belgium and more1Active, not recruitingApr 10, 202721

How it is read

Names in the registry

  • “AMG 691”, 2 entries

Codes read as this program: AMG691.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
AMG 691 (Amgen): development program | ClinicalTrials.gg